Background In the PREVAIL study, enzalutamide significantly improved clinical outcomes
versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate …

Background Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being
explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) …

Purpose: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53
profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Colorectal cancer (CRC) is currently the most common type of cancer in Japan, and its
prognosis has improved because of development of diagnosis and advancement in …

Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …

Background Taxane–platinum combinations have shown promising activity in metastatic
castration-resistant prostate cancers in single-group clinical studies but not in randomised …

Purpose: DNA damage repair (DDR) defects are common across cancer types and can
indicate therapeutic vulnerability. Optimal exploitation of DDR defects in prostate cancer …

The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for
men with castration-resistant prostate cancer (CRPC). However, not all patients respond …

Background Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the
disease. Several recent studies have identified genomic alterations in mCRPC, but the …